Acelyrin deprioritises lead therapy despite Phase III win, fires 33% of staff
As part of pipeline reprioritisation, Acelyrin has dropped izokibep and will instead start Phase III trials for lonigutamab in Q1 2025. Acelyrin has decided to shake up its pipeline; while the company...